Eric S. Winer, MD, on Metastatic Breast Cancer: Debate on a Research Tool 
    		2017 San Antonio Breast Cancer Symposium
    	
    	
    	
    
        Eric S. Winer, MD, of the Dana-Farber Cancer Institute, addresses the much-discussed controversy over whether all women diagnosed with metastatic breast cancer should undergo next-generation sequencing.
    
    
    
    
       
       
    		
		
		
        
		
		
		
		Elizabeth A. Mittendorf, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the growing role of immunotherapy in treating breast disease, the evidence of biomarkers that may be associated with response to therapy, and the opportunities to perform robust correlative studies.
			
			
     	
    
       
       
    		
		
		
        
		
		
		
		Lisa A. Carey, MD, of the University of North Carolina, discusses the long-term follow-up of CALGB 40502/NCCTG N063H, a phase III study of weekly paclitaxel compared with weekly nanoparticle albumin bound nab-paclitaxel or ixabepilone with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (Abstract GS3-06).
			
			
     	
    
       
       
    		
		
		
        
		
		
		
		Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute, discusses study findings on a comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive breast cancer (Abstract GS4-03).
			
			
     	
    
       
       
    		
		
		
        
		
		
		
		Eun-Sil Shelley Hwang, MD, of Duke University Medical Center, discusses study findings on primary endocrine therapy for estrogen receptor–positive ductal carcinoma in situ (Abstract GS5-05).
			
			
     	
    
       
       
    		
		
		
        
		
		
		
		Melinda Telli, MD, of the Stanford University School of Medicine, discusses the current status of treatment for advanced TNBC, and new therapeutic strategies now being used for better outcomes.